Summit Therapeutics PLC (NASDAQ: SMMT) has received a consensus rating of “Hold” from analysts covering the stock, according to MarketBeat.com. The analysis stems from evaluations by seventeen research firms, revealing a blend of recommendations: three analysts suggest selling, four advocate for holding, while nine recommend buying, and one has issued a strong buy.
The average price target set by these brokers for the next twelve months stands at approximately $33.08. This figure reflects the analysts’ expectations based on current market conditions and Summit’s performance. Several firms have recently updated their evaluations.
Piper Sandler set a price target of $40.00 in a report released on January 14, while HC Wainwright reiterated a buy recommendation on the same day. Conversely, Weiss Ratings maintained a “sell (d-)” rating as of October 8. Additionally, Zacks Research upgraded the stock from a “strong sell” to a “hold” rating on October 13. Guggenheim reaffirmed a buy rating and also set the price target at $40.00 on October 22.
Current Stock Performance and Financial Metrics
As of Thursday, Summit Therapeutics shares opened at $17.04. The stock’s performance is reflected in its moving averages, with a 50-day simple moving average of $17.75 and a 200-day average of $21.15. The company, with a market capitalization of $13.14 billion, has experienced a fifty-two week low of $15.55 and a high of $36.91.
In its latest financial disclosures, Summit Therapeutics reported earnings per share (EPS) of ($0.31) for the quarter ending October 20, missing the consensus estimate of ($0.14) by $0.17. Analysts project that the company will post an EPS of (0.30) for the current fiscal year.
About Summit Therapeutics
Summit Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for serious and life-threatening diseases. The company adopts a targeted approach to drug discovery, emphasizing novel mechanisms of action that set its candidates apart from existing therapies. Its lead asset, ridinilazole (formerly known as SMT19969), aims to address Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration.
For those interested in keeping up with the latest news and ratings for Summit Therapeutics, MarketBeat.com offers a free daily newsletter that summarizes these updates.
